Oncotarget

Research Papers:

YpT1-2N0 rectal cancer after neoadjuvant chemoradiation has lower survival compared with pT1-2N0 rectal cancer

Jue-feng Wan _, Ji Zhu, Gui-chao Li, Wen-jie Sun and Zhen Zhang

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:41056-41062. https://doi.org/10.18632/oncotarget.5379

Metrics: PDF 1266 views  |   HTML 1432 views  |   ?  


Abstract

Jue-feng Wan1,2, Ji Zhu1,2, Gui-chao Li1,2, Wen-jie Sun1,2, Zhen Zhang1,2

1Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China

2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

Correspondence to:

Zhen Zhang, e-mail: zhenzhang6@hotmail.com

Keywords: rectal cancer, adjuvant chemotherapy, risk factors, good response, SEER

Received: July 09, 2015     Accepted: September 02, 2015     Published: October 21, 2015

ABSTRACT

Pathologic T1-2N0 rectal cancer shows an excellent prognosis without preoperative or postoperative chemoradiation. However, oncologic outcome of ypT1-2N0 remains unclear and undetermined. Thus, the aim of this study was to compare the survival of ypT1-2 and pT1-2 rectal cancer patients after radical resection and identify risk factors of ypT1-2 rectal cancer in Surveillance, Epidemiology, and End Results Program (SEER)-registered rectal cancer patients. The results showed that ypT1-2N0 rectal cancer after neoadjuvant chemoradiation has lower survival compared with pT1-2N0 rectal cancer and mucinous/signet-ring cancer and less than 12 lymph nodes retrieval were two risk factors in ypT1-2 patients. These results suggest that ypT1-2 patients with one or two risk factors may benefit from postoperative adjuvant chemotherapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 5379